JPJeffrey S. Phillips

Jeffrey S. Phillips

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jeffrey S. Phillips has a total of 283 co-authors. Here are the top co-authors by number of shared publications:

  • David John Irwin

    Penn Frontotemporal Degeneration Center, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia; and

    15 shared publications
  • Murray Grossman

    Penn Frontotemporal Degeneration Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States

    15 shared publications
  • Corey T. McMillan

    Penn Frontotemporal Degeneration Center, Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA USA

    10 shared publications
  • David A. Wolk

    Penn Alzheimer’s Disease Research Center, University of Pennsylvania, Philadelphia, PA USA

    10 shared publications
  • Corey T. McMillan

    Department of Neurology, University of Pennsylvania Perelman School of Medicine , Philadelphia, PA 19104

    7 shared publications
  • David A Wolk

    Department of Neurology, University of Pennsylvania , Philadelphia, PA 19104

    6 shared publications

Latest Publications

  • Open Access

    Spatial covariance of mGluR5 density and structural degeneration in behavioral variant frontotemporal degeneration

    by Melanie A. Matyi, Maggie K. Pecsok, Christopher A. Olm, Hamsanandini Radhakrishnan, Laynie Dratch, Vivianna M. Van Deerlin, Emma Rhodes, Jeffrey S. Phillips, Philip A. Cook, James C. Gee, et al.

    Post-mortem human brain tissue and in vivo imaging studies of behavioral variant frontotemporal degeneration (bvFTD) suggest that metabotropic glutamate receptors (mGluR) may be vulnerable to the disease process. However, these studies lack evidence demonstrating how loss of mGluR relates to clinical features of bvFTD, hindering efforts to identify appropriate therapeutic strategies. Thus, we leveraged existing normative receptor density maps, and a large cohort of individuals with bvFTD to elucidate relationships among structural degeneration, glutamatergic receptor density, and clinical features. We obtained receptor density maps from the neuromaps repository, which contains positron emission tomography-derived receptor maps across many neurotransmitter systems, including mGluR5 and N-methyl-D-aspartate (NMDA). We quantified the spatial covariance of structural degeneration and glutamate receptor density maps in 106 individuals with bvFTD and 165 cognitively unimpaired (CU) individuals. Covariance of each participant’s regional cortical volumes and normative receptor density in each region of the Schaefer 100 (7 network) parcellation was computed. Negative covariance indicates a high spatial correspondence such that regions with greater structural degeneration also have high receptor density. Within bvFTD, we tested whether greater spatial covariance of structural degeneration and receptor density maps were associated with disease stage and severity, executive function, and neuropsychiatric symptoms. Comparing bvFTD with CU, we observed significant spatial covariance of structural degeneration and mGluR5, but not NMDA. In bvFTD, greater covariance of structural degeneration and mGluR5 maps was associated with more advanced disease stage (p = .003) and severity (p < .001), and worse category (p < .001) and letter-guided (p < .001) fluency and digit span backward (p = .0257) but not neuropsychiatric symptom severity. Neurodegeneration in bvFTD appears to preferentially affect cortical regions with higher normative mGluR5 density, as reflected by spatial covariance between structural degeneration and mGluR5 maps in a clinically well-characterized cross-sectional cohort. Furthermore, greater covariance of mGluR5 density and structural degeneration with both disease severity and executive dysfunction elucidates potential neural mechanisms of core clinical features of bvFTD. Future work examining in vivo glutamate could provide further insight into the natural history of glutamate dysfunction in bvFTD, facilitating testing of glutamatergic therapies.

  • Open Access

    Associations of 18 F‐flortaucipir tau PET with quantitative tau histopathology in the medial temporal lobe

    by Jeffrey S Phillips, Amanda E Denning, Lisa M Levorse, Christopher A Brown, Laura E.M. Wisse, Sanaz Arezoumandan, Sandhitsu R. Das, Eddie B. Lee, Ricardo Insausti, John L. Robinson, et al.

    Background: 18 F‐Flortaucipir is widely used for positron emission tomography (PET) imaging of Alzheimer’s disease (AD)‐type tau, but its sensitivity in early Braak stages has been questioned, and hippocampal uptake is at least partially confounded by off‐target binding. We investigated associations between antemortem PET uptake and digitally‐quantified tau and TDP‐43 neuropathology. Methods: Participants ( n = 14, Figure 1) included 5 people with no/low AD neuropathologic change (ADNC) at autopsy, 2 intermediate, and 7 high. Clinical diagnoses included normal cognition ( n = 2), AD ( n = 5), dementia with Lewy bodies ( n = 2), Parkinson’s disease dementia ( n = 1), corticobasal syndrome ( n = 2), and posterior cortical atrophy ( n = 2). We used the Automated Segmentation of Hippocampal Subfields T1 MRI pipeline to segment anterior and posterior hippocampus, Brodmann’s areas (BA) 35 (transentorhinal cortex) & 36, and entorhinal cortex. 18 F‐Flortaucipir standardized uptake value ratios (SUVRs) were computed relative to inferior cerebellar grey matter and averaged across hemispheres. Postmortem sampling comprised hippocampal subiculum, CA1, CA2, CA3, and dentate gyrus; BA35 and BA36; and entorhinal cortex. FFPE‐brain tissue was immunostained using PHF1 and phospho‐specific TDP‐43 antibodies and digitally imaged. Two different weakly supervised learning algorithms, Wildcat, were trained to identify tau tangles and threads; or somatic and neuritic phosphorylated TDP‐43 (pTDP‐43) inclusions. Each pathology type was quantified by summary statistics on Wildcat heatmaps, averaged over hippocampal subfields; and over BA35/entorhinal cortex (Denning et al., 2024). We computed non‐parametric correlations between SUVRs and pathology measures at a=0.05 with false discovery rate correction. Results: Tangles were associated with SUVRs in BA35/entorhinal cortex (Spearman’s r=0.59, p = 0.029; Figure 2A). The mean hippocampal tangle measure was associated with SUVRs in both anterior (r=0.77, p = 0.002) and posterior (r=0.77, p = 0.002) hippocampus (Figure 2B‐C). Associations between SUVR and tau threads were marginally significant (Figure 2D‐F). In BA35/entorhinal cortex, 9/9 intermediate‐high ADNC cases had SUVRs above an established positivity cutoff of 1.23 (Figure 3). PET SUVRs were not associated with somatic or neuritic pTDP‐43 measures. Conclusion: Results suggest 18 F‐flortaucipir is sensitive to tau burden in early Braak‐stage regions and primarily reflects neurofibrillary tangles rather than thread‐like tau inclusions.

  • Open Access

    Connectivity as a universal predictor of tau progression in atypical Alzheimer’s disease

    by Hannah de Bruin, Colin Groot, Henryk Barthel, Gérard N Bischof, Ganna Blazhenets, Ronald Boellaard, Baayla D C Boon, Matthias Brendel, David M Cash, William Coath, et al.

    The link between regional tau load and clinical manifestation of Alzheimer’s disease (AD) highlights the importance of characterizing spatial tau distribution across disease variants. In typical (memory-predominant) AD, the spatial progression of tau pathology mirrors the functional connections from temporal lobe epicentres. However, given the limited spatial heterogeneity of tau in typical AD, atypical (non-amnestic-predominant) AD variants with distinct tau patterns provide a key opportunity to investigate the universality of connectivity as a scaffold for tau progression. In this large-scale, multicentre study across 14 international sites, we included cross-sectional tau-PET data from 320 individuals with atypical AD (n = 139 posterior cortical atrophy/PCA-AD; n = 103 logopenic variant primary progressive aphasia/lvPPA-AD; n = 35 behavioural variant AD/bvAD; n = 43 corticobasal syndrome/CBS-AD), with a subset of individuals (n = 78) having longitudinal tau-PET data. Additionally, as an independent sample, we included regional post-mortem tau stainings from 93 atypical AD patients from two sites (n = 19 PCA-AD, n = 32 lvPPA-AD, n = 23 bvAD, n = 19 CBS-AD). Gaussian mixture modelling was used to harmonize different tau-PET tracers by transforming tau-PET standardized uptake value ratios to tau positivity probabilities (a uniform scale ranging from 0% to 100%). Using linear regression, we assessed whether brain regions with stronger resting-state functional MRI-based functional connectivity, derived from healthy elderly controls in the Alzheimer’s Disease Neuroimaging Initiative (ADNI), showed greater covariance in cross-sectional and longitudinal tau-PET and post-mortem tau pathology. Furthermore, we examined whether functional connectivity of tau-PET epicentres (i.e. the top 5% of regions with the highest baseline tau load) and tau-PET accumulation epicentres (i.e. the top 5% of regions with the highest tau accumulation rates) was associated with cross-sectional and longitudinal tau patterns. Our findings show that tau-PET epicentres aligned with clinical variants, e.g. a visual network predominant pattern in PCA-AD (‘visual AD’) and left-hemispheric temporal predominance, particularly within the language network, in lvPPA-AD (‘language AD’). Moreover, more strongly functionally connected regions showed correlated concurrent tau-PET levels (confirmed with post-mortem data) and tau-PET accumulation rates. The functional connectivity profile of tau-PET epicentres and accumulation epicentres corresponded to tau-PET progression patterns, with higher tau-PET levels and accumulation rates in functionally close regions, and lower tau-PET levels and accumulation rates in functionally distant regions. Our data are consistent with the hypothesis that tau propagation occurs along functional connections originating from local epicentres, across all AD clinical variants. Since tau proteinopathy is a major driver of neurodegeneration and cognitive decline, this finding may advance personalized medicine and participant-specific end points in clinical trials.


  • Open Access

    Executive dysfunction relates to salience network desegregation in behavioral variant frontotemporal dementia

    by Melanie A. Matyi, Hamsanandini Radhakrishnan, Christopher A. Olm, Jeffrey S. Phillips, Philip A. Cook, Emma Rhodes, James C. Gee, David J. Irwin, Corey T. McMillan, Lauren Massimo

    Background: The organization of the brain into distinct networks increases (i.e., differentiation) during development and decreases (i.e., de-differentiation) during healthy aging, changes that are associated with improvements and worsening of cognition, respectively. Given that behavioral variant frontotemporal degeneration (bvFTD) is a neurodegenerative disease associated with executive dysfunction and selective vulnerability of the salience network, we tested the hypotheses that bvFTD structural networks are de-differentiated compared to cognitively normal controls (CNC) and that network de-differentiation relates to worse executive function. Methods: In a sample of 90 patients with bvFTD and 71 age-matched CNC with diffusion MRI data we generated probabilistic tractography maps and calculated system segregation, a metric that compares within-network to between-network connectivity, to reflect the extent to which brain networks were differentiated. Patients with bvFTD also completed tests of executive function (digit span backwards, phonemic fluency, category fluency) and a control task (lexical retrieval). We assessed group differences in system segregation, reflecting network differentiation, and, within bvFTD, associations between system segregation and neuropsychological test performance. Results: Compared to CNC, patients with bvFTD exhibited lower system segregation of the salience ( p < .001) and global brain network ( p = .008). In bvFTD, lower salience network system segregation was associated with worse executive function ( p corrected = .029) but not lexical retrieval. Conclusions: Results demonstrate associations between executive dysfunction and salience network de-differentiation in patients with bvFTD. Our findings indicate that brain network de-differentiation, reflecting reduced neural capacity for specialized processing, may contribute to the emergence of executive dysfunction in bvFTD.

  • Open Access

    White matter integrity is lower in non‐amnestic than amnestic Alzheimer's disease and differs by clinical syndrome

    by Jeffrey S Phillips, Nagesh Adluru, Moo K Chung, Hamsi Radhakrishnan, Christopher A Olm, Philip A. Cook, James C. Gee, Sanaz Arezoumandan, Katheryn A Q Cousins, David A Wolk, et al.

    Background: Amnestic mild cognitive impairment and Alzheimer’s disease (aAD) exhibit degeneration of white matter (WM) tracts preceding overt cognitive decline. However, WM changes in non‐amnestic AD (naAD) are understudied. We hypothesized patterns of WM degeneration would differ between aAD and naAD.Methods: We compared WM degeneration, assessed by 30‐direction diffusion‐weighted imaging (DWI), in 41 individuals with aAD; 67 with naAD diagnoses including logopenic‐variant primary progressive aphasia (lvPPA), posterior cortical atrophy (PCA), behavioral variant AD (bvAD), and corticobasal syndrome (CBS); and 45 with normal cognition (Table 1). We performed deterministic tractography between 148 cortical/subcortical regions; connectivity was quantified by generalized fractional anisotropy (GFA). Tractwise GFA and regional grey matter (GM) volumes were converted to W‐scores adjusting for age and sex. We contrasted GFA between groups using regression models covarying for MMSE score. A mixed effects model was used to assess associations between tractwise GFA and volume of GM endpoints. Additionally, we computed the number of connected components in each person’s brain graph (i.e., number of subgraphs created by progressively stricter thresholds) across 100 GFA values. We contrasted this topological metric between groups and assessed its associations with MMSE and disease duration.Results: GM volume was lower in naAD and aAD than controls (both p<0.0001) but did not differ between patient groups (p=0.81). aAD and naAD patients had shared WM degeneration in corpus callosum, cingulum, and inferior/superior longitudinal fasciculi; however, WM degeneration was more severe in naAD (Fig. 1). In lvPPA, WM degeneration was left‐lateralized; in PCA, GFA was reduced in bilateral parietal, occipital, and temporal areas (Fig. 2). Across groups, GM and WM degeneration were significantly associated [F(1,20442)=326.0, p<0.0001]. Topological analysis indicated naAD but not aAD patients had lower global connectivity than controls. A higher component number (indicating reduced connectivity) was associated with longer disease duration and lower MMSE.Conclusion: Associations between GM volume and GFA suggest WM degeneration in naAD is related to AD pathologic change and not an independent process. Greater WM disease in naAD than aAD was not attributable to GM atrophy or symptom severity. Finally, topological metrics may serve as objective markers of global disease progression.

  • Open Access

    White matter integrity is lower in non‐amnestic than amnestic Alzheimer's disease and differs by clinical syndrome

    by Jeffrey S Phillips, Nagesh Adluru, Moo K Chung, Hamsi Radhakrishnan, Christopher A Olm, Philip A. Cook, James C. Gee, Sanaz Arezoumandan, Katheryn A Q Cousins, David A Wolk, et al.

    Background: Amnestic mild cognitive impairment and Alzheimer’s disease (aAD) exhibit degeneration of white matter (WM) tracts preceding overt cognitive decline. However, WM changes in non‐amnestic AD (naAD) are understudied. We hypothesized patterns of WM degeneration would differ between aAD and naAD.Methods: We compared WM degeneration, assessed by 30‐direction diffusion‐weighted imaging (DWI), in 41 individuals with aAD; 67 with naAD diagnoses including logopenic‐variant primary progressive aphasia (lvPPA), posterior cortical atrophy (PCA), behavioral variant AD (bvAD), and corticobasal syndrome (CBS); and 45 with normal cognition (Table 1). We performed deterministic tractography between 148 cortical/subcortical regions; connectivity was quantified by generalized fractional anisotropy (GFA). Tractwise GFA and regional grey matter (GM) volumes were converted to W‐scores adjusting for age and sex. We contrasted GFA between groups using regression models covarying for MMSE score. A mixed effects model was used to assess associations between tractwise GFA and volume of GM endpoints. Additionally, we computed the number of connected components in each person’s brain graph (i.e., number of subgraphs created by progressively stricter thresholds) across 100 GFA values. We contrasted this topological metric between groups and assessed its associations with MMSE and disease duration.Results: GM volume was lower in naAD and aAD than controls (both p<0.0001) but did not differ between patient groups (p=0.81). aAD and naAD patients had shared WM degeneration in corpus callosum, cingulum, and inferior/superior longitudinal fasciculi; however, WM degeneration was more severe in naAD (Figure 1). In lvPPA, WM degeneration was left‐lateralized; in PCA, GFA was reduced in bilateral parietal, occipital, and temporal areas (Figure 2). Across groups, GM and WM degeneration were significantly associated [F(1,20442)=326.0, p<0.0001]. Topological analysis indicated naAD but not aAD patients had lower global connectivity than controls. A higher component number (indicating reduced connectivity) was associated with longer disease duration and lower MMSE.Conclusion: Associations between GM volume and GFA suggest WM degeneration in naAD is related to AD pathologic change and not an independent process. Greater WM disease in naAD than aAD was not attributable to GM atrophy or symptom severity. Finally, topological metrics may serve as objective markers of global disease progression.

  • Open Access

    Greater white matter degeneration and lower structural connectivity in non-amnestic vs. amnestic Alzheimer’s disease

    by Jeffrey S. Phillips, Nagesh Adluru, Moo K. Chung, Hamsanandini Radhakrishnan, Christopher A. Olm, Philip A. Cook, James C. Gee, Katheryn A. Q. Cousins, Sanaz Arezoumandan, David A. Wolk, et al.

    Introduction: Multimodal evidence indicates Alzheimer’s disease (AD) is characterized by early white matter (WM) changes that precede overt cognitive impairment. WM changes have overwhelmingly been investigated in typical, amnestic mild cognitive impairment and AD; fewer studies have addressed WM change in atypical, non-amnestic syndromes. We hypothesized each non-amnestic AD syndrome would exhibit WM differences from amnestic and other non-amnestic syndromes.Materials and methods: Participants included 45 cognitively normal (CN) individuals; 41 amnestic AD patients; and 67 patients with non-amnestic AD syndromes including logopenic-variant primary progressive aphasia (lvPPA, n = 32), posterior cortical atrophy (PCA, n = 17), behavioral variant AD (bvAD, n = 10), and corticobasal syndrome (CBS, n = 8). All had T1-weighted MRI and 30-direction diffusion-weighted imaging (DWI). We performed whole-brain deterministic tractography between 148 cortical and subcortical regions; connection strength was quantified by tractwise mean generalized fractional anisotropy. Regression models assessed effects of group and phenotype as well as associations with grey matter volume. Topological analyses assessed differences in persistent homology (numbers of graph components and cycles). Additionally, we tested associations of topological metrics with global cognition, disease duration, and DWI microstructural metrics.Results: Both amnestic and non-amnestic patients exhibited lower WM connection strength than CN participants in corpus callosum, cingulum, and inferior and superior longitudinal fasciculi. Overall, non-amnestic patients had more WM disease than amnestic patients. LvPPA patients had left-lateralized WM degeneration; PCA patients had reductions in connections to bilateral posterior parietal, occipital, and temporal areas. Topological analysis showed the non-amnestic but not the amnestic group had more connected components than controls, indicating persistently lower connectivity. Longer disease duration and cognitive impairment were associated with more connected components and fewer cycles in individuals’ brain graphs.Discussion: We have previously reported syndromic differences in GM degeneration and tau accumulation between AD syndromes; here we find corresponding differences in WM tracts connecting syndrome-specific epicenters. Determining the reasons for selective WM degeneration in non-amnestic AD is a research priority that will require integration of knowledge from neuroimaging, biomarker, autopsy, and functional genetic studies. Furthermore, longitudinal studies to determine the chronology of WM vs. GM degeneration will be key to assessing evidence for WM-mediated tau spread.


  • Evaluation of ATN PD Framework and Biofluid Markers to Predict Cognitive Decline in Early Parkinson Disease

    by Katheryn A.Q. Cousins, David J. Irwin, Thomas F. Tropea, Emma Rhodes, Jeffrey Phillips, Alice S. Chen-Plotkin, Michael C. Brumm, Christopher S. Coffey, Ju Hee Kang, Tanya Simuni, et al.

    In Parkinson disease (PD), Alzheimer disease (AD) copathology is common and clinically relevant. However, the longitudinal progression of AD CSF biomarkers-β-amyloid 1-42 (Aβ42), phosphorylated tau 181 (p-tau181), and total tau (t-tau)-in PD is poorly understood and may be distinct from clinical AD. Moreover, it is unclear whether CSF p-tau181 and serum neurofilament light (NfL) have added prognostic utility in PD, when combined with CSF Aβ42. First, we describe longitudinal trajectories of biofluid markers in PD. Second, we modified the AD β-amyloid/tau/neurodegeneration (ATN) framework for application in PD (ATNPD) using CSF Aβ42 (A), p-tau181 (T), and serum NfL (N) and tested ATNPD prediction of longitudinal cognitive decline in PD. Participants were selected from the Parkinson's Progression Markers Initiative cohort, clinically diagnosed with sporadic PD or as controls, and followed up annually for 5 years. Linear mixed-effects models (LMEMs) tested the interaction of diagnosis with longitudinal trajectories of analytes (log transformed, false discovery rate [FDR] corrected). In patients with PD, LMEMs tested how baseline ATNPD status (AD [A+T+N±] vs not) predicted clinical outcomes, including Montreal Cognitive Assessment (MoCA; rank transformed, FDR corrected). Participants were 364 patients with PD and 168 controls, with comparable baseline mean (±SD) age (patients with PD = 62 ± 10 years; controls = 61 ± 11 years]; Mann-Whitney Wilcoxon: p = 0.4) and sex distribution (patients with PD = 231 male individuals [63%]; controls = 107 male individuals [64%]; χ2: p = 1). Patients with PD had overall lower CSF p-tau181 (β = -0.16, 95% CI -0.23 to -0.092, p = 2.2e-05) and t-tau than controls (β = -0.13, 95% CI -0.19 to -0.065, p = 4e-04), but not Aβ42 (p = 0.061) or NfL (p = 0.32). Over time, patients with PD had greater increases in serum NfL than controls (β = 0.035, 95% CI 0.022 to 0.048, p = 9.8e-07); slopes of patients with PD did not differ from those of controls for CSF Aβ42 (p = 0.18), p-tau181 (p = 1), or t-tau (p = 0.96). Using ATNPD, PD classified as A+T+N± (n = 32; 9%) had worse cognitive decline on global MoCA (β = -73, 95% CI -110 to -37, p = 0.00077) than all other ATNPD statuses including A+ alone (A+T-N-; n = 75; 21%). In patients with early PD, CSF p-tau181 and t-tau were low compared with those in controls and did not increase over 5 years of follow-up. Our study shows that classification using modified ATNPD (incorporating CSF Aβ42, CSF p-tau181, and serum NfL) can identify biologically relevant subgroups of PD to improve prediction of cognitive decline in early PD.


  • Open Access

    Tau maturation in the clinicopathological spectrum of Lewy body and Alzheimer's disease

    by Sanaz Arezoumandan, Katheryn A.Q. Cousins, Daniel T. Ohm, MaKayla Lowe, Min Chen, James Gee, Jeffrey S. Phillips, Corey T. McMillan, Kelvin C. Luk, Andres Deik, et al.

    Objective: Alzheimer's disease neuropathologic change and alpha‐synucleinopathy commonly co‐exist and contribute to the clinical heterogeneity of dementia. Here, we examined tau epitopes marking various stages of tangle maturation to test the hypotheses that tau maturation is more strongly associated with beta‐amyloid compared to alpha‐synuclein, and within the context of mixed pathology, mature tau is linked to Alzheimer's disease clinical phenotype and negatively associated with Lewy body dementia.Methods: We used digital histology to measure percent area‐occupied by pathology in cortical regions among individuals with pure Alzheimer's disease neuropathologic change, pure alpha‐synucleinopathy, and a co‐pathology group with both Alzheimer's and alpha‐synuclein pathologic diagnoses. Multiple tau monoclonal antibodies were used to detect early (AT8, MC1) and mature (TauC3) epitopes of tangle progression. We used linear/logistic regression to compare groups and test the association between pathologies and clinical features.Results: There were lower levels of tau pathology (β = 1.86–2.96, p < 0.001) across all tau antibodies in the co‐pathology group compared to the pure Alzheimer's pathology group. Among individuals with alpha‐synucleinopathy, higher alpha‐synuclein was associated with greater early tau (AT8 β = 1.37, p < 0.001; MC1 β = 1.2, p < 0.001) but not mature tau (TauC3 p = 0.18), whereas mature tau was associated with beta‐amyloid (β = 0.21, p = 0.01). Finally, lower tau, particularly TauC3 pathology, was associated with lower frequency of both core clinical features and categorical clinical diagnosis of dementia with Lewy bodies.Interpretation: Mature tau may be more closely related to beta‐amyloidosis than alpha‐synucleinopathy, and pathophysiological processes of tangle maturation may influence the clinical features of dementia in mixed Lewy‐Alzheimer's pathology.


  • Open Access

    Shared and disparate transcriptomic signatures associated with cortical atrophy change in genetic behavioral variant frontotemporal degeneration

    by Ting Shen, Jacob W Vogel, Vivianna M Van Deerlin, Laynie Dratch, Eddie B Lee, Jeffrey S Phillips, Murray Grossman, Lauren Massimo, David J. Irwin, Corey T McMillan

    Background: Cortical atrophy is a common manifestation in behavioral variant frontotemporal degeneration (bvFTD). Distinct atrophy patterns across different form of genetic bvFTD may be shaped by their different underlying biology. This study aimed to use an integrative imaging transcriptomics approach to identify shared and disparate transcriptomic signatures associated with cortical thickness changes in bvFTD with mutations in C9orf72, GRN, and MAPT.Method: We extracted cortical thickness for 124 sporadic bvFTD patients, 32 C9orf72‐bvFTD, 11 GRN‐bvFTD, and 13 MAPT‐bvFTD mutation cases. Cortical thickness differences were computed between genetic and sporadic bvFTD patients, adjusted for age, sex and disease duration. Normative gene expression profiles were extracted from the Allen Human Brain Atlas. Partial least squares regression model was used to rank all genes by their correlation between gene expression and cortical thickness differences in each genetic form of bvFTD. Functional and cell‐type enrichment analyses were then conducted to explore underlying biological processes of top‐ranked genes.Result: Relative to sporadic bvFTD, cortical thickness was decreased in temporal regions in C9orf72‐bvFTD, frontotemporal regions in MAPT‐bvFTD, and cortical atrophy was more extensively distributed in GRN‐bvFTD. We identified sets of genes that were positively or negatively associated with cortical thickness differences for each genetic form of bvFTD. Enrichment analyses indicated that genes negatively associated with GRN‐bvFTD atrophy were mainly involved in synaptic pathways and neuron projection development. These GRN‐bvFTD negatively associated genes were enriched in neurons, while the positively associated genes were mainly enriched in glial cells (Figure 1). The genes positively associated with MAPT‐bvFTD atrophy were involved in synaptic pathways and cognition‐related terms, and were preferentially expressed in neurons (Figure 2). Furthermore, an oligodendrocyte precursor cell enriched gene, Protocadherin‐15 (PCDH15), was found to be negatively associated with cortical thickness change in both C9orf72‐bvFTD and GRN‐bvFTD.Conclusion: Spatial distribution of cortical structural change in each genetic form of bvFTD might be modulated by the expression of genes that were involved in common and different functional pathways, coupled with different cellular signatures. Identification of shared and disparate transcriptomic signatures will contribute to further understanding of potential genetic basis of heterogeneity for different genetic forms of bvFTD.